About Medicxi
Medicxi is a venture capital firm founded in 2016. It is primarily based out of London, United Kingdom. As of Aug 2026, Medicxi is an active investor, having invested in 86 companies, with 1 new investment in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series B round of Vaderis Overall, Medicxi portfolio has seen 16 IPOs and 26 acquisitions including key companies like Evotec, Adaptive Biotechnologies and Vaxcyte. A lot of funds co-invest with Medicxi, with names like Orbimed sharing a substantial percentage of its portfolio. Medicxi has team of 23 people including 11 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Medicxi's List of Top Investments
Medicxi has a portfolio of 86 companies. Their most notable investments are in Janpix and Janpix.Their portfolio spans across United States, United Kingdom, Netherlands and 8 more locations. They have invested in Life Sciences, High Tech, HealthTech and 3 other sectors, across stages such as Series A, Series B and 4 more. Here is the list of top investments by Medicxi:
1. Ultrahuman
Developer of wearable health monitors and metabolic glucose tracking devices. These products track sleep, recovery, and metabolic markers to provide health insights. The hardware includes rings for sleep monitoring, continuous glucose monitors, and red light therapy equipment. Software platforms interpret health data and blood test results to assist with physiological performance and wellness management.
Key facts about Ultrahuman
- Founded Year: 2019
- Location: Bengaluru (India)
- Annual Revenue: ₹500 - ₹1,000 Cr as on Mar 31, 2025
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $173M
- Employee Count: 333 as on Mar 31, 2026
- Investors: Qualcomm Ventures, Steadview and 48 Others
- Latest Funding Round: Venture Debt, Sep 03, 2026, $*****
- Highlight: Editors' Pick
2. Evotec
AI-driven life science company accelerating drug discovery and development. It is focused on pioneering drug discovery and preclinical development using advanced technologies, deep disease expertise, and integrated R&D platforms. It accelerates the creation of new therapies across modalities, including small molecules and biologics, to bring life-changing medicines to patients faster.
Key facts about Evotec
- Founded Year: 1993
- Location: Hamburg (Germany)
- Annual Revenue: €500M - €1B as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $25.1M
- Employee Count: 4,690 as on Aug 31, 2026
- Investors: Gilde Healthcare, Eiffel Investment Group and 22 Others
- Latest Funding Round: Grant (prize money), Jan 08, 2026, $*****
- Highlight: Public
Provider of clinical diagnostics, and drug discovery for immune diseases. The company's immune profiling sequencing technology immunoSEQ enables the characterization of the immune system, helping scientists & clinicians in research and drug development. The company also offers clonoSEQ for monitoring Minimal Residual Disease (MRD) in blood-based cancers. Also, develops cell therapies, vaccines, and antibody molecules for infectious diseases.
Key facts about Adaptive Biotechnologies
- Founded Year: 2009
- Location: Seattle (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $419M
- Employee Count: 645 as on Aug 31, 2026
- Investors: HTIF, Foresite Capital and 21 Others
- Latest Funding Round: Series F, Jan 22, 2018, $*****
- Highlight: Public
4. Vaxcyte
Developer of vaccines to treat infectious diseases. The company uses the cell-free protein synthesis platform called XpressCFTM along with the company's proprietary knowledge base to design and produce protein carriers and antigens for site-specific conjugation (building blocks of vaccines) for developing antigens and pneumococcal conjugate vaccines (VAS-24). It is also developing vaccines for invasive, pneumococcal diseases, otitis media, strep infections, and periodontitis.
Key facts about Vaxcyte
- Founded Year: 2013
- Location: Foster City (United States)
- Stage: Public
- Total Funding till date: $283M
- Employee Count: 589 as on Aug 31, 2026
- Investors: HTIF, Foresite Capital and 16 Others
- Latest Funding Round: Series D, Apr 03, 2020, $*****
- Highlight: Public
Developer of therapies for treating gastrointestinal diseases. The lead drug candidate Vonoprazan, which is a potassium-competitive acid blocker (P-CAB). It is being investigated for treating gastroesophageal reflux disease (GERD)/erosive esophagitis.
Key facts about Phathom Pharmaceuticals
- Founded Year: 2019
- Location: Menlo Park (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $90M
- Employee Count: 442 as on Aug 31, 2026
- Investors: BVF Partners, Sagard and 11 Others
- Latest Funding Round: Conventional Debt, May 15, 2019, $*****
- Highlight: Public
Medicxi's Year-on-Year Investment Trends
Medicxi has invested in 86 companies over the last 10 years, with an average of 4 new investments annually in the last 10 years. In 2025, it made 3 investments, while as of Aug 2026, it has made 3 investments in this year. Its most recent first time investment was in Altesa Biosciences and most recent follow-on round was in Vaderis.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 2 | 3 |
2025 | 1 | 2 | 3 |
2024 | 6 | 0 | 6 |
2023 | 2 | 0 | 2 |
2022 | 1 | 1 | 2 |
2021 | 6 | 2 | 8 |
2020 | 7 | 2 | 9 |
2019 | 4 | 0 | 4 |
2018 | 4 | 0 | 4 |
2017 | 7 | 0 | 7 |
Medicxi's Investments by Stage
Medicxi has made 19 investments in Series A stage with an average round size of $30.4M, 12 investments in Series B stage with an average round size of $61.8M and 4 investments in Series C stage with an average round size of $80.8M.Stage of entry | No. of Investments |
|---|---|
Series A | 19 |
Series B | 12 |
Series C | 4 |
Post IPO | 2 |
Seed | 2 |
Others | 2 |
Note: We have considered here, only first round of investments
Medicxi's Investments by Sector
Medicxi has a diverse portfolio, with companies operating in the Life Sciences, Sustainability Tech, High Tech and Enterprise Applications. Notably, it has invested in 81 Tech companies, 73 Enterprise (B2B) companies, 9 Software companies and at least 3 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 41 |
Sustainability Tech | 5 |
High Tech | 3 |
Enterprise Applications | 1 |
Note: We have considered here, only first round of investments
Medicxi's Investments by Geography
Medicxi has made most investments in United States (21), followed by United Kingdom where it has made 15 investments.Country | No. of Investments |
|---|---|
United States | 21 |
United Kingdom | 15 |
Netherlands | 2 |
Switzerland | 2 |
China | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Medicxi's recent investments
Medicxi has made 3 investments in 2026 so far. Vaderis and Fore are the latest among them.Here are the most recent investments by Medicxi:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Aug 11, 2026 | Switzerland | Series B | 6488 | [+6] | |
Jul 07, 2026 | United States | Series D | 4507 | [+13] | |
Feb 13, 2026 | United States | Series B | 5004 | [+3] | |
Dec 10, 2025 | China | Series B | 4623 | [+5] | |
Apr 30, 2025 | United States | Series D | 8034 | [+6] |
IPOs and Publicly Listed companies in Medicxi's Portfolio
16 of Medicxi's portfolio companies have become public. Aura Biosciences got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Oct 2021 at marketcap of $398M and NewAmsterdam Pharma got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of undefined.Here are Medicxi's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Oct 29, 2021 | Apr 12, 2019 | Series D | 9091 | |
Feb 08, 2021 | - | - | 9374 | |
Aug 07, 2020 | - | - | 1512 | |
Jun 12, 2020 | Jun 07, 2018 | Series C | 9889 | |
Oct 25, 2019 | May 15, 2019 | Series C | 5276 |
Acquired companies in Medicxi's Portfolio
26 companies from Medicxi's portfolio have been acquired. The most recent acquisition was Centessa Pharmaceuticals in Mar 2026 by Lilly for $*****.Here are Medicxi's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 31, 2026 | - | - | 6804 | |
Jan 20, 2026 | Dec 23, 2024 | Post IPO | 8366 | |
Dec 12, 2025 | - | - | 7509 | |
Jul 22, 2025 | Sep 23, 2024 | Series B | 1352 | |
Apr 03, 2024 | Feb 13, 2024 | Series B | 9065 |
Team profile of Medicxi
Medicxi has a team of 23 members including 11 Partners and 6 Venture Partners located in United Kingdom, Switzerland and 1 more location. Medicxi's team sits on the board of 2 companies.Here is a list of top team members in Medicxi:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Cambridge | - | - | |
Partner | London | - | ||
Partner | Geneva | - | ||
Partner | Switzerland | - | - | |
Partner | London | - | ||
Partner | Switzerland | - | ||
Partner | Boston | - | - | |
Partner | London | - | - | |
Partner | London | - | - | |
Partner | London | - | - | |
Partner | United Kingdom | - | - |
Co-investors of Medicxi
Over the past 10 years, 190 investors have co-invested in Medicxi's portfolio companies. This includes funds and angels.
- Invested before Medicxi: Index Ventures, Advent Life Sciences and 71 others have invested in rounds before Medicxi. There are 4 companies where Index Ventures has invested before Medicxi and 3 companies where Advent Life Sciences has invested before Medicxi.
- Top Co-investors of Medicxi: 74 investors entered a company along with Medicxi. These include investors like Orbimed (7 companies).
- Invested after Medicxi: A total of 43 investors have invested in Medicxi's portfolio after their investments. Top Investors include RA Capital Management (2 companies), Omega Funds (2 companies) and Janus Henderson Investors (1 company).
Recent News related to Medicxi
•
FORE Biotherapeutics Raises $67.4M to Advance BRAF Cancer TherapyVentureburn•Jul 08, 2026•Fore, Primer Ventures, Axil Capital, Medicxi and 3 others
•
Altesa BioSciences raises $75M to advance respiratory medEndpoints•Feb 19, 2026•ABOGADOS Y TECNICOS ASOCIADOS SL, Atlantic Partners Asia, Sanofi, Altesa Biosciences and 5 others
•
D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical ProgramsPR Newswire•Dec 10, 2025•Temasek, IDG Capital, D3 Bio, HSG and 5 others
•
Medicxi Announces €500 Million Fund V to Build and Back Innovative Biotechnology CompaniesPR Newswire•Nov 14, 2025•Medicxi
•
Servier Acquires Treatment for Fragile X Syndrome from Kaerus for Up to $450MEuropa Press•Sep 08, 2025•Kaerus Bioscience, Servier, Medicxi
•
FORE Biotherapeutics Raises $38 Million in Series D FinancingBusiness Wire•May 22, 2025•Fore, SR One, Medicxi, Orbimed and 3 others
•
Curevo Raises $110 Million to Advance Amezosvatein Shingles VaccineBakersfield•Mar 17, 2025•Curevo, Medicxi, Vaxcyte, Vicebio and 12 others
•
Ottimo Pharma Raises over $140 Million in Series A Financingintelligence360•Jan 10, 2025•Ottimo Pharma, Orbimed, Avoro Capital, Samsara BioCapital and 6 others
•
RAPT Therapeutics Announces $150 Million Private PlacementBakersfield•Dec 23, 2024•RAPT, The Column Group, RTW Investments, Redmile Group and 8 others
•
Great Pharma Raises Over $ 140mFinSMEs•Dec 19, 2024•Orbimed, Avoro Capital, Samsara BioCapital, Decheng Capital and 7 others
